echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Safety data released for more than 500,000 vaccinations of Sinopharm China's new bio-new crown inactivated vaccine

    Safety data released for more than 500,000 vaccinations of Sinopharm China's new bio-new crown inactivated vaccine

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    At present, the new crown vaccination campaign has been widely launched in China.


    The new crown inactivated vaccine developed by the Wuhan Institute of Biological Products and Beijing Institute of Biological Products under Sinopharm China Biotechnology Co.


    Two new inactivated vaccines developed by the Wuhan Institute of Biology and Beijing were approved to be included in the emergency use of China's new crown vaccine in June and July 2020.


    The overall adverse reaction rate is low, and no serious adverse reactions have been found

    The overall adverse reaction rate is low, and no serious adverse reactions have been found

    The system monitored a total of 519,543 vaccination information and found 5164 pieces of adverse reaction information.


    Picture source: reference [1]

    Adverse reactions of vaccination are generally relieved within 3-4 days

    Adverse reactions of vaccination are generally relieved within 3-4 days

    Safety information shows that local reactions after vaccination mainly occur on the day of vaccination and within 24 hours after vaccination.


    Reference materials [1]

    The lowest adverse reaction rate among the elderly over 60

    The lowest adverse reaction rate among the elderly over 60

    Analyzing the incidence of adverse reactions according to population characteristics, it was found that the incidence of adverse reactions in women was 1.


    According to age, the incidence of adverse reactions was the highest among people aged 12-18, reaching 11.


    Picture source: reference [1]

    Some discussion

    Some discussion

    During the discussion of the paper, the researchers pointed out that the safety data obtained during this emergency use process was significantly better than the safety results of the inactivated vaccine in the phase 2 clinical trial.


    The types of adverse reactions found in this study are similar to those in clinical trials, and compared with other types of inactivated vaccines, the adverse reaction rate of the new coronavirus inactivated vaccine is also relatively low.


    The author pointed out at the end of the paper that increasing the vaccination rate and gradually establishing herd immunity is one of the most effective ways to stop the spread of the new crown epidemic.


    Reference materials:

    [1] Yang et al.


    Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.